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Abstract
Background. No guidelines exist concerning treatment of
asymptomatic bacteriuria in renal transplant recipients
(RTR). Because of scarce clinical symptoms and fear of
complications, such episodes are frequently treated based
on subjective criteria without clear clinical benefit, with the
risk of selecting resistant pathogens.
Methods. We retrospectively analysed the outcome of 334
asymptomatic Escherichia coli (E. coli) and Enterococcus
faecalis (E. faecalis) bacteriuria that occurred in 77 RTR
later than 1 month post-transplantation. We distinguished:
Type I, high-grade bacteriuria with pyuria; Type II, high-
grade bacteriuria without pyuria; Type III, low-grade bac-
teriuria with pyuria and Type IV, low-grade bacteriuria
without pyuria.
Results. None of the 334 episodes was followed by acute
rejection or chronic pyelonephritis. One hundred and one
(30%) episodes were treated [32 (62%) Type I, 38 (45%)
Type II, 13 (36%) Type III and 18 (11%) Type IV]. Evolu-
tion to symptomatic urinary tract infection (UTI) was similar
between treated and untreated episodes (0/101 versus 4/233,
P¼ 0.32). The four UTI resolved favourably without further
complication upon treatment. Persistent asymptomatic bac-
teriuria occurred in 45 (46%) treated episodes (2 Type I, 27
Type II, 8 Type III and 9 Type IV), with selection of resist-
ant pathogen in 35 cases (78%). Spontaneous bacterial
clearance occurred in 138 (59%) untreated episodes (15
Type I, 23 Type II, 9 Type III and 91 Type IV). Negative
control cultures tended to be more frequent in treated Type I
(P ¼ 0.09) and in untreated Type II episodes (P ¼ 0.08).
Conclusion. Restricting antibiotic treatments for asympto-
matic low-grade bacteriuria and high-grade bacteriuria in
the absence of pyuria, occurring later than 1 month post-
transplantation, might be safe in RTR.
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infection
Introduction
Despite the common use of prophylactic trimethoprim–
sulphamethoxazole (TMP–SMX) during the first 6 months
post-transplantation, infections of the urinary tract (UTI)
remain the most common form of bacterial infection in renal
transplant recipients (RTR) [1]. Retrospective studies have
suggested that the frequency of UTI in RTR is higher than in
the general population, especially during the first month
posttransplantation [2, 3]. The incidence ranges from 4 to
74% in this population [1–5]. UTI after renal transplantation
have been associated with graft loss, chronic rejection, pap-
illary necrosis and an increased mortality [1, 2]. Specific risk
factors include advanced age, female gender, reflux kidney
disease prior to transplantation, use of azathioprine and de-
ceased donor [1, 2]. Escherichia coli (E. coli) and Enter-
occocus spp. are the most frequently isolated bacterial
pathogens accounting for >50% of UTI in this population
[1, 2, 6, 7]. For E. coli, a unique pattern of uropathogenic
serotypes and adherence factors have been recently
suggested to contribute to allograft injury in RTR [8]. In
non-RTR, clinicians distinguish between upper-UTI (pyelo-
nephritis), lower-UTI (cystitis) and colonization of the lower
urinary tract (asymptomatic bacteriuria) [9]. These distinc-
tions are made on the bases of clinical symptoms, quantita-
tive urine cultures and urine sediment analysis. In the
absence of symptoms, positive urinary cultures generally
do not require treatment [10–12]. However, in RTR, such
distinctions are generally not made because of the fear of
scarce clinical symptoms and more rapid serious complica-
tions [1, 13]. In the absence of clear prospective data, precise
treatment guidelines do not exist for this frequent situation
[1]. The latest guidelines issued by the ‘Infectious Diseases
Society of America’ state ‘No recommendations can be made
for screening, or treatment of asymptomatic bacteriuria in
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renal transplant. . .recipients (C-III)’ [12]. As a consequence,
treatment strategies for asymptomatic bacteriuria have been
more liberal and indiscriminate in RTR, and physicians tend
to treat such episodes according to their personal discretion.
Lengths of treatments vary considerably, and many episodes
of asymptomatic bacteriuria (potentially colonizations) are
treated, leading to repeated exposure of RTR to antimicrobial
agents. The only objective criteria available to the clinician
during an episode of asymptomatic bacteriuria are the level of
bacteriuria and of pyuria. We wondered whether the degree of
these two criteria influences the outcome of both treated and
untreated asymptomatic bacteriuria. We therefore conducted a
retrospective study to determine the outcome of both treated
and untreated E. coli and E. faecalis asymptomatic bacteriuria
that occurred later than 1 month post-transplantation, classi-
fied in four distinct groups based on culture and urinary
sediment.
Materials and methods
Patients
This retrospective study was conducted on 196 consecutive patients who
received a renal allograft at the University Hospital in Geneva, Switzerland
from January 1999 to October 2004. Using the database of the Central
Bacteriology Laboratory and the clinical records of the University Hospi-
tal, we identified 334 distinct episodes of asymptomatic E. faecalis or
E. coli bacteriuria, which occurred at least 1 month post-transplantation
in 65 kidney recipients and 12 kidney–pancreas or kidney–islets recipients
during this period. Fifty-eight per cent were female and the mean age at
transplantation was 49 years (range 21–73). Eighty-three per cent had
received a kidney from a deceased donor (Table 1). The bile drainage of
all pancreas recipients was enteric. Causes of end-stage renal diseases are
listed in Table 1.
Immunosuppressive therapy
Several protocols were used during the study for induction and mainte-
nance immunosuppression. For induction therapy, 60 kidney recipients
received the monoclonal anti-IL2 receptor antagonist basiliximab and 5
received rabbit anti-thymocyte globulin (ATG). Corticosteroids were
given to all patients. Maintenance immunosuppression was based on a
combination of mycophenolate mofetil (MMF) with tacrolimus or cyclo-
sporine. Corticosteroids were progressively decreased from initially 1 mg/
kg/day to 5 mg/day at 3 months post-transplantation. Induction therapy for
kidney–pancreas recipients consisted of ATG in combination with cortico-
steroids and for kidney–islets recipients of daclizumab. Maintenance ther-
apy for kidney–pancreas recipients was based on a combination of
tacrolimus with MMF or sirolimus, with progressive discontinuation of
corticosteroids over 6 months, and for kidney–islets recipients on a com-
bination of tacrolimus and sirolimus. At the time of asymptomatic bacter-
iuria, corticosteroids were given in combination with MMF and
tacrolimus/cyclosporine to 68 patients (Table 1). Six patients were receiv-
ing a combination therapy of tacrolimus and MMF and three patients a
combination therapy of tacrolimus and sirolimus.
Antibiotic prophylaxis
All patients received a perioperative antibiotic prophylaxis consisting in
three doses of 1.2 g amoxicillin–clavulanate, given at 8 h intervals, the first
administered 1 h prior to incision. Post-operative prophylaxis consisted of
TMP–SMX 480 mg/day given for 6 months. Valgancyclovir for cytome-
galovirus (CMV) prophylaxis was given to all high-risk recipients (D1/
R) and to all patients receiving ATG for induction therapy. Intermediate
risk patients (D1/R1 and D/R1) were screened weekly with an ultra-
sensitive polymerase chain reaction and treated pre-emptively with val-
gancyclovir in the case of positive CMV viraemia.
Parameters studied
We reviewed the medical records for information on demographic char-
acteristics, date of transplantation and positive cultures, concomitant bac-
teraemia, urine analysis and clinical presentation both at the time of
positive cultures and the follow-up visit, type of immunosuppression at
the time of the positive cultures, type and length of treatment, acute re-
jection within 1 month of bacteriuria, death and renal graft loss during the
study period. Patients with clinical symptoms (fever, pain, pollakiuria,
dysuria) and/or laboratory results (ultrasonographic signs of pyelonephritis
or bacteraemia) suggestive of UTI, or with polymicrobial bacteriuria with
three or more pathogens suggestive of contaminated samples as well as
carriers of urinary tract catheters/urethral stents were excluded. Episodes
of asymptomatic bacteriuria occurring within 1 month of an acute rejection
were excluded.
The physician in charge freely decided whether or not to treat the
episode as well as the type and length of antibiotics.
Definitions
Following international definitions of bacteriuria and pyuria [1, 12], we
classified the different episodes of asymptomatic bacteriuria in four dis-
tinct categories:
Type I: high-grade bacteriuria (105 cfu/mL) with pyuria [10 white
blood cell (WBC)/field],
Type II: high-grade bacteriuria without pyuria (<10 WBC/field),
Type III: low-grade bacteriuria (<105 cfu/mL) with pyuria and
Type IV: low-grade bacteriuria without pyuria.
An episode was only considered successfully treated if pyuria and
bacteriuria disappeared at the following control and there was no recur-
rence of bacteriuria with the same pathogen during a period of 3 weeks. A
negative control culture (microbiological cure) was defined as a control
culture with <102 cfu/mL.
Asymptomatic bacteriuria (whatever type) found at the control follow-
ing an initial episode, whether treated or not, was not considered a new
episode. Two episodes in a single patient were only considered distinct if
the following two conditions were satisfied:
(1) both episodes had to be at least 3 weeks apart in the absence of
antimicrobial therapy,
(2) both episodes had to be separated by at least one normal control urine
analysis (absence of pyuria) and a sterile urine culture.
Laboratory investigations
Urine analysis with microscopic examination and urine culture were ob-
tained routinely from every patient during their scheduled follow-up visits
(once a week during the first 2 months after transplantation; twice a month
during the next 2 months; once every 3 weeks for the following 2 months
and once a month thereafter), as well as when clinical symptoms suggested
an UTI. The urine samples were collected following a clean catch protocol.
Table 1. Characteristics of 77 patients with asymptomatic bacteriuria
Age (mean and range) 50 (11–73)
Female 45 (58%)
Kidney transplant 65
Kidney–pancreas or kidney–islets transplant 12
Deceased donor 64 (83%)
Immunosuppressive treatment at the time of bacteriuria
Steroids 1 MMF 1 tacrolimus/cyclosporine 68
Tacrolimus 1 MMF 6
Tacrolimus 1 sirolimus 3
Cause of end-stage renal disease
Diabetes 10
Glomerulonephritis 6
Hypertensive nephrosclerosis 7
Polycystic kidney 21
IgA nephropathy 10
Reflux nephropathy 8
Others 15
Mortality 9 (12%)
Renal graft loss 4 (5%)
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E. faecalis and E. coli were identified at the Central Laboratory of Bacteri-
ology via standard clinical microbiology methods. The antimicrobial sus-
ceptibility was determined by the disk diffusion method according to the
latest available CLSI guidelines [14].
Statistical analysis
Each episode of bacteriuria was considered distinct and no distributional
assumptions were made, we used the Mann–Whitney U-test to compare
means. Two-sided Fisher’s exact tests were used to analyse differences
between group proportions. Statistical significance was claimed for P 
0.05 (two sided). Statistical analyses were performed using SPSS 11.0
(SPSS, Chicago, IL).
Results
General outcome
None of the episodes was followed by an acute rejection in
the next month or evolved toward chronic pyelonephritis.
Nine patients (12%) died during the study period, none of
the deaths was secondary to a URI (Table 1). Four patients
(5%) developed graft failure due to chronic rejection.
Types of URI and colonization episodes
Asymptomatic bacteriuria was a frequent and recurrent
event as 334 distinct episodes occurred in the 77 patients
culture-positive patients (4.4 episodes/patient), including
52 Type I, 85 Type II, 36 Type III and 161 Type IV epi-
sodes (Figure 1, Table 2). All 77 patients developed more
than two distinct episodes of asymptomatic bacteriuria.
There was no link between types of previous episodes
and types of succeeding episodes. The mean time between
distinct episodes was 2.3 months. The median time from
transplantation to asymptomatic bacteriuria was similar for
Types III and IV episodes (3.2 and 3.7 months, respec-
tively), whereas Types I and II episodes tended to develop
later (7.8 and 4.8 months, respectively) (Table 2).
Microbiology
E. faecalis was isolated slightly more frequently in all types
of asymptomatic bacteriuria (62% of Type I, 58% of Type
II, 58% of Type III and 66% of Type IV episodes) (Table
2). Types I, II and IV episodes due to E. faecalis occurred
earlier that those due to E. coli (mean months: 8.3 versus
19.7, 5.7 versus 16.7, 8 versus 14.5; P< 0.05). None of the
E. faecalis isolates was vancomycin resistant. Most E. coli
isolates were TMP–SMX resistant. No difference in pro-
gression to symptomatic UTI was detected between both
pathogens (E. coli, 1 of 209, versus E. faecalis, 3 of 127;
P ¼ 0.15).
Types and lengths of antimicrobial treatments
Sixty-two per cent Type I episodes were treated, as com-
pared to 45% Type II, 36 % Type III and 11% Type IV
episodes (Figure 1). All 77 patients experienced at least one
treated and one untreated episode. We observed no link
between treatment of previous episodes and treatments of
succeeding episodes. Mean treatment durations for Type I
episodes were 12.2 days, respectively, as compared to 11.5,
10.4 and 11.4 for Types II, III and IV episodes, respectively
(Table 2). No significant differences were noted in treat-
ment durations between E. coli and E. faecalis bacteriuria.
E. faecalis bacteriuria was treated with either amoxicillin
or amoxicillin–clavulanate. E. coli episodes were treated
with ciprofloxacin, norfloxacin, amoxicillin, amoxicillin–
clavulanate or fosfomycin, depending on the result of the
antimicrobial susceptibility test. Adequacy of antimicrobial
treatments exceeded 95%.
Fig. 1. Flow chart of types and treatments of 334 asymptomatic bacteriuria episodes.
Table 2. Microbiology and characteristics of 334 episodes of asymptomatic bacteriuriaa
Type I Type II Type III Type IV
Total number of episodes 52 85 36 161
E. coli episodes (n ¼ 127) 20 36 15 55
E. faecalis episodes (n ¼ 209) 32 49 21 106
Median time (months) from transplantation to episode and IQR 7.8 (1.8–21.1) 4.8 (1.1–13.9) 3.2 (1.4–8.1) 3.7 (1.1–12.5)
Mean duration of treatment (days) and total range 12.7 (2–40) 11.5 (1–30) 10.4 (3–15) 11.4 (3–30)
aIQR, interquartile range.
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Outcome of treated bacteriuria
None of the 101 treated episodes progressed toward symp-
tomatic UTI or to a bacteriuria of another type according to
our classification. Among the 32 treated Type I episodes, 2
episodes were followed by persistent Type I asymptomatic
bacteriuria with the same pathogen (Table 3). Only 11
(29%) of the 38 treated Type II episodes were followed
by sterile control urine cultures defining microbiological
cure (Table 3). In the other 27 episodes, the control culture
showed a persistent Type II bacteriuria, of which 13 epi-
sodes were due to the original pathogen. Strikingly, in eight
of these episodes, the initially susceptible pathogen had
become resistant to the given antimicrobial treatment. In
the remaining 14 episodes, the control culture grew a new
pathogen resistant to the initial antimicrobial treatment. Of
the 13 treated Type III episodes, only 5 (39 %) were fol-
lowed by a sterile control culture. After treatment comple-
tion, the original pathogen grew again in the control
cultures in three episodes, and in one of these, the initial
pathogen had become resistant (Table 3). In five episodes,
the control culture grew a new pathogen resistant to the
preceding antimicrobial therapy. Of the 18 treated Type
IV episodes, only 9 (50%) had sterile control cultures. In
five episodes, the control urine culture remained positive
for the initial pathogen, and in two of these episodes, the
pathogen had acquired resistance. In four episodes, the
control cultures were positive for a new resistant pathogen
(Table 3). Therefore, only 55 of the 101 (55%) treated
episodes were followed by a sterile control culture.
Outcome of untreated bacteriuria
Only 4 of the 233 (2%) untreated episodes progressed to-
ward symptomatic UTI, including 1 Type I (E. coli) and 3
Type IV episodes (2 E. coli and 1 E. faecalis). All these
events responded to subsequent antimicrobial therapy with-
out further complications (Table 4). None of the 70 un-
treated Types II and III episodes were complicated by
symptomatic UTI. Surprisingly, for 15 of the 20 (75%)
untreated Type I episodes, the initial pathogen could not
be isolated in the control urine culture. Similarly, for 23 of
the 47 (49%) untreated Type II episodes, the control urine
culture was negative for the initial pathogen. The control
culture of nine of the 23 (39%) untreated Type III episodes
was negative for the initial pathogen. Two untreated Type
III episodes (9%) progressed into Type I episodes (Table
4). In 91 of the 143 (65%) untreated Type IV episodes, the
initial pathogen spontaneously cleared. Four (3%) Type IV
episodes progressed into Type II episodes. Therefore, spon-
taneous bacterial clearance was observed in 138 of 233
(59%) untreated episodes.
Outcome of treated versus untreated
We observed no differences when comparing progression
toward symptomatic UTI between all treated and untreated
episodes (0/101 versus 4/233, P ¼ 0.32). Spontaneous
clearance of the initial pathogen in all untreated episodes
was as frequent as microbiological cure of treated episodes
(138/233 versus 55/101, P ¼ 0.47). Sterile control cultures
tended to be more frequent in treated as compared to un-
treated Type I episodes (30/32 versus 15/20, P ¼ 0.09) and
tended to be more frequent in untreated than treated Type II
episodes (23/47 versus 11/38, P ¼ 0.08).
Discussion
Asymptomatic bacteriuria occurring in non-RTR is classified
as urinary tract colonization that does not require treatment
Table 3. Outcome of 101 treated asymptomatic bacteriuria
Initial type of treated bacteriuria
Result of control urine culture
Symptomatic UTI Sterile control culture (%)
Persistent asymptomatic bacteriuria (%)
Persistent initial pathogen New pathogen
Type I (n ¼ 32) 0 30 (94%) 2 (6%) 0
Type II (n ¼ 38) 0 11 (29%) 13 (34%) 14 (37%)
Type III (n ¼ 13) 0 5 (38%) 3 (23%) 5 (39%)
Type IV (n ¼ 18) 0 9 (50%) 5 (28%) 4 (22%)
Table 4. Outcome of 233 untreated asymptomatic bacteriuria
Initial type of untreated bacteriuria
Result of control urine culture
Symptomatic UTI Sterile control culture (%)
Persistent asymptomatic bacteriuria with initial
pathogen (%)
Type I Type II Type III Type IV
Type I (n ¼ 20) 1 (5%) 15 (75%) 4 (20%) 0 0 0
Type II (n ¼ 47) 0 23 (49%) 0 24 (51%) 0 0
Type III (n ¼ 23) 0 9 (39%) 2 (9%) 0 12 (52%) 0
Type IV (n ¼ 143) 3 (2%) 91 (64%) 0 4 (3%) 0 45 (31%)
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following international guidelines [12]. Indeed, antibiotic
treatment does not reduce the risk of subsequent UTI, is often
unable to eradicate the colonizing organism and frequently
leads to the selection of resistant organisms [12, 15, 16].
However, it is a common belief that asymptomatic bacteriuria
in RTR has a different clinical significance, especially during
the first month post-transplantation because the allograft is
particularly susceptible to injuries at this time [13]. Under-
lying diseases such as advanced diabetic neuropathy,
combined with denervation of the allograft and immunosup-
pressive medications, especially corticosteroids, affect the
reliability of clinical symptoms [1]. This population is not
only more prone to complications of UTI because of an in-
cidence of reflux as high as 50% [17], but acute pyelonephritis
in RTR also represents a risk factor for long-term impairment
of allograft function [18]. Moreover, asymptomatic bacteriu-
ria itself has been suggested to cause subclinical damage to
the allograft due to inflammation, as increased IL-8 levels
have been measured during such episodes in RTR [19]. How-
ever, this was not associated with a reduced graft function
during a 1-year follow-up. Most studies that investigated the
importance of bacteriuria in RTR were uncontrolled [20–22].
As a consequence of a high incidence of severe UTI with
significant mortality and graft loss, several authors suggested
antimicrobial prophylaxis. Indeed in observational studies,
the UTI rates dropped at the time TMP–SMX was introduced
for the prophylaxis of pneumocystis pneumonia [23, 24].
However, no study analysed the outcome of untreated versus
treated asymptomatic bacteriuria in the post-transplant pe-
riod, and there is conflicting evidence that treating asympto-
matic bacteriuria could preserve allograft function [1, 25].
The fear of serious complications must be balanced against
the consequences of repeated exposure to antimicrobial
treatments, which include selection of resistant bacteria
(methicillin-resistant Staphylococcus aureus, extended-
spectrum Beta-lactamases-producing Gram-negative bacilli
and vancomycin-resistant enterocci) [5, 26] and yeasts, as
well as elevated costs and drug-mediated side effects.
In this retrospective study, we analysed the outcome of
101 treated and 233 untreated asymptomatic bacteriuria,
caused by either E. coli or E. faecalis, in 77 RTR that oc-
curred later than 1 month post-transplantation. We classified
these episodes into four categories depending on objective
laboratory results (magnitude of bacteriuria and pyuria) in
order to identify potential subgroups with different out-
comes. Episodes due to E. faecalis tended to be more fre-
quent and occurred earlier than those due to E. coli. This
probably reflects the protective effect against E. coli of the
TMP–SMX chemoprophylaxis routinely administered dur-
ing the first 6 months after transplantation. None of the
treated and untreated episodes was followed by acute rejec-
tion or chronic pyelonephritis. Symptomatic UTI within 1
month of asymptomatic bacteriuria was a rare event that
occurred only after four untreated episodes and we observed
no difference in progression toward symptomatic UTI be-
tween treated and untreated episodes. This suggests that in
our population restricting antibiotic treatment was safe and
did not expose these patients to a higher risk of early infec-
tious complications.
Spontaneous bacterial clearance was a frequent event
occurring in 59% of all untreated episodes. In contrast,
the microbiological benefit of antimicrobial treatment was
low as bacteriuria persisted in 45% of all treated episodes.
Antibiotics were not only often unable to eradicate the
initial pathogen but also frequently selected resistant bac-
teria. Therefore, when all episodes were analysed together,
resolution of bacteriuria was not more frequent in treated as
compared to untreated episodes (P ¼ 0.47). These findings
are again similar to those described in non-RTR, especially
spinal cord injury patients, where treatment of urinary tract
colonization has been associated with various bacterial re-
sistance without clinical benefit [15, 16]. Our study did not
identify clear differences between the four subcategories
based on objective laboratory results (quantitative urinary
culture and sediment). However, for Type I (high-grade
bacteriuria and pyuria) episodes, treated bacteriuria tended
to be followed more frequently by negative control cultures
than untreated episodes (P ¼ 0.09). In contrast, for Type II
episodes (high-grade bacteriuria with no significant pyuria)
control cultures tended to be more frequently negative in
untreated than treated episodes (P ¼ 0.08). These trends
point toward a potential value of pyuria in distinguishing
episodes with high-grade bacteriuria that might benefit
from treatment.
Our retrospective study presents important limitations, in
particular a possible patient selection bias. Although we
used a strict time frame and objective microbiological
and laboratory criteria, we cannot exclude that some
episodes were not completely independent. However, all
episodes were distinct and could be analysed for their short-
term outcome; resolution or not of bacteriuria. Also, the
decision on whether or not to treat might have been influ-
enced by different co-morbidities as well as variations in
provider practice. However, while these factors clearly
limit direct comparison between treated and untreated
groups, they could not influence the good outcome of
the untreated and the rather disappointing microbiologic
evolution of the treated groups. Another limitation is our
choice to restrict the analysis to E. coli and E. faecalis
bacteriuria and to episodes occurring <1 month post-
transplantation. These restrictions were based on the
potential hypersusceptibility of the allograft early after
transplantation, and the fact that these two pathogens
accounted for >50% of all episodes. Including episodes
caused by less frequent pathogens with significant differ-
ences in virulence such as Pseudomonas aeruginosa or
Staphylococcus aureus could potentially dilute the obser-
vations. As a consequence, we cannot exclude that outcome
of early untreated asymptomatic bacteriuria as well as
untreated bacteriuria due to other pathogens might be differ-
ent. Also, our data does not allow for the exclusion of a
potential impact of not treating asymptomatic bacteriuria on
long-term renal function. Indeed as all other patients, the
four patients who developed chronic rejection had pre-
sented a mixture of several distinct episodes of treated
and untreated asymptomatic bacteriuria, precluding the
analysis of any potential link.
Our data suggests that similarly as in non-RTR not all
episodes of asymptomatic bacteriuria in RTR should be
treated with antibiotics. Distinctions between UTI that
require antibiotic treatment and colonization that can be
carefully watched without immediate treatment might
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avoid selecting resistant pathogens that render treatment of
real infections more difficult. Our retrospective study needs
confirmation by a prospective placebo-controlled random-
ized trial. Such a study should allow designing evidence-
based treatment guidelines of asymptomatic bacteriuria in
RTR, based on objective data namely quantitative urine
culture and sediment, avoiding both unacceptable clinical
risks and unnecessary exposure to repeated antimicrobial
agents.
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